Navigation Links
Nile Therapeutics Receives Positive NASDAQ Panel Decision
Date:3/2/2011

SAN MATEO, Calif., March 2, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on March 1, 2011, the Company received a positive determination from the NASDAQ Listing Qualifications Panel (the "Panel") indicating that the Panel had granted the Company's request for an extension to remain listed on The NASDAQ Stock Market ("NASDAQ").  In accordance with the terms of the Panel's decision, the Company's continued listing on NASDAQ is subject to the Company evidencing compliance with NASDAQ's minimum $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2), by May 31, 2011.  The Company may evidence compliance with the bid price requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by May 31, 2011.  

As previously disclosed, on November 30, 2010, the Company was notified by NASDAQ that its securities were subject to delisting based upon the Company's failure to satisfy the minimum bid price requirement.  The Company subsequently attended a hearing before the Panel at which it presented its plan to regain compliance with the minimum bid price requirement by May 31, 2011.  May 31, 2011 constitutes the full extent of the Panel's discretion to grant the Company an extension to remedy the bid price deficiency.  While the Company is working to timely satisfy the terms of the Panel's decision, there can be no assurance that it will be able to do so.  

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderi
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support ... heart failure, today announced that it expects revenues ... approximately $53 million, bringing expected full-year 2013 revenues ... revenue growth of 87% for 2013 above 2012 ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... event for buyers and sellers of high-value chemistry, will ... conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 attendees ... will take part in the conference, which includes on-site ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... results for the third quarter and nine months ended ... is available through Echo,s website at www.echotx.com . ...
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
Cached Medicine Technology:Echo Therapeutics Announces Third Quarter 2011 Financial Results 2Echo Therapeutics Announces Third Quarter 2011 Financial Results 3Echo Therapeutics Announces Third Quarter 2011 Financial Results 4Echo Therapeutics Announces Third Quarter 2011 Financial Results 5James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... says that workers with health insurance cover return to work ... said that research // conducted for it ... by workers returning early from illnesses. ,The current ... needed an operation and 76 uninsured workers. It was found ...
... press that it has completed the vaccination for all the ... // poultry were vaccinated across Vietnam. , ... the Ministry of Agriculture and Rural Development. ,Some ... whereas others received a booster dose for prevention of the ...
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... Health Minister was issued notice after a complaint that said ... transfers // and appointments for medical and Para ... Justice K Sreedharan and Upa Lok Ayukta N Krishnan Nair ... others. ,Kerala Government Medical Officers Association (KGMOA) has ...
... medicine was safer than western alternatives // has ... watchdog said on Wednesday. ,The leaflet could dissuade ... serious medical conditions, the Advertising Standards Authority (ASA) said. ... claimed that serious medical problems such as cancer could ...
... ENT and Plastic Surgeon Dr. P. Thulasi Das and his ... Fluid (CSF) // leak to a 25 ... The patient was suffering from meningitis. Meningitis is the inflammation ... meningitis is caused by bacterial or fungal infections. Cerebrospinal fluid ...
Cached Medicine News:Health News:Chinese medicine leaflet broke advertising code 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
Triad Plus PVP-I Scrub Solution has broad-spectrum germicidal action.This special formula is designed to help break down body oils and yet limit the bubbles the surfactants allowing easy removal and ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... are designed for individual application and are ... in nursing homes, home healthcare settings, blood ... hospital departments. This unit dose pouch contains ... germicidal and cleansing agent. Hydrogen Peroxide's chief ...
Medicine Products: